Tracking a new lupus Drug's Real-World impact
NCT ID NCT06673043
Summary
This study aims to see how well the drug anifrolumab works for controlling lupus in real-world medical practice in Poland. It will follow 100 adult patients with lupus who are already receiving this medication through a national program for about 30 months. The main goal is to measure changes in their lupus disease activity and see how many patients achieve low disease activity or remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS ERYTHEMATOSUS, SYSTEMIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBydgoszcz, Poland
-
Research Site
RECRUITINGBytom, Poland
-
Research Site
RECRUITINGGdansk, Poland
-
Research Site
RECRUITINGKatowice, Poland
-
Research Site
RECRUITINGKrakow, Poland
-
Research Site
RECRUITINGLodz, Poland
-
Research Site
RECRUITINGLublin, Poland
-
Research Site
RECRUITINGPoznan, Poland
-
Research Site
RECRUITINGRzeszów, Poland
-
Research Site
RECRUITINGWarsaw, Poland
-
Research Site
RECRUITINGWroclaw, Poland
Conditions
Explore the condition pages connected to this study.